Alivus Life Sciences Ltd reports Q2FY27 revenue of ₹6,820 million, up 16% YoY, and PAT of ₹1,968 million, up 51.3%.
- EBITDA rose 47% YoY to ₹2,851 million; margin was 41.8%, up 880 bps YoY.
- PAT margin was 28.9%, up 680 bps YoY.
- Free cash flow was ₹2,702 million; cash and cash equivalents, including short-term investments, totalled ₹10,116 million at September 30, 2026.